Skip to content

Released May 4, 2022, after the close

10-Q filed May 4, 2022, 34 days after period end · 0000950170-22-007389

Q1 2022 · 10-Q
Revenue$18.41M+65.3% vs Q1 2021+7.9% vs Q4 2021
Net Income-$65.69MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.68N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$74,467,000N/M
Operating Cash Flow-$64,613,000N/M
Free Cash Flowderived-$74,697,000N/M
Margins · derived
Operating margin-404.4%+10.3 pt vs Q1 2021
Net margin-356.7%+47.9 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Revenue$18.41M$11.14M$2.52M$2.63M
Net Income-$65.69M-$45.09M-$33.52M-$19.76M
EPS Diluted-$0.68-$0.48-$0.44-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR